[Table], Evidence Table I.5. Cardiovascular Adverse Events, Monotherapies - Relative Effectiveness and Cost-Effectiveness of Methods of Androgen Suppression in the Treatment of Advanced Prostate Cancer

Warning: The NCBI web site requires JavaScript to function. more...

	Cardiovascular Nonspecified			Peripheral Edema			Embolic Events/Phlebitis/Venous Thrombosis			Stroke/TIA			Angina/MI
	N Pts	%	N Studies	N Pts	%	N Studies	N Pts	%	N Studies	N Pts	%	N Studies	N Pts	%	N Studies
Orchiectomy	144	0.0	1	101	12.9	1	101	1.0	1	101	2.0	1	242	7.0	2

DES	139	26.6	3	245	22.0	3	463	3.3-5.6	6	270	3.7	3	343	3.8	4

Cyproterone	477	4.2	4			0	84	2.4	1	0		0	84	3.6	1

NSAA			0	1127	8.6	3	54	0.0	2	34	2.9	1	34	5.9	1

LHRH	873	1.3	4	152	18.4	2	306	0.0--1.0	3	124	0.0	1	259	6.9	2

Relative Effectiveness and Cost-Effectiveness of Methods of Androgen Suppression in the Treatment of Advanced Prostate Cancer.

Evidence Reports/Technology Assessments, No. 4.

Aronson N, Seidenfeld J, Samson DJ, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.